Ignacio Melero
Impact in
- Oncology top 0.02%
- Cancer Immunotherapy and Biomarkers
- Hepatology top 0.05%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 243
- Cancer Immunotherapy and Biomarkers 217
- Immunology 221
- Immunotherapy and Immune Responses 154
- Immune Cell Function and Interaction 29
- T-cell and B-cell Immunology 28
- Immune cells in cancer 12
- Co-authors
- Jose Luis Perez-Gracia (64 shared papers)Miguel F. Sanmamed (56 shared papers)Maria Esperanza Rodriguez-Ruiz (56 shared papers)Bruno Sangro (37 shared papers)Sandra Hervás‐Stubbs (46 shared papers)Jesús Prìeto (47 shared papers)David Sancho (14 shared papers)Lieping Chen (20 shared papers)
- Journals
- Annals of Oncology (45 papers)Clinical Cancer Research (44 papers)Journal for ImmunoTherapy of Cancer (35 papers)OncoImmunology (20 papers)Cancer Discovery (16 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Ignacio Melero
448 papers receiving 42.4k citations
Ignacio Melero's Hit Papers
Peers
Comparison fields: 5 of 148
- Oncology 18.4k
- Hepatology 7k
- Immunology 13k
- Cancer Research 1.5k
- Genetics 876
Countries citing papers authored by Ignacio Melero
This map shows the geographic impact of Ignacio Melero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ignacio Melero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ignacio Melero more than expected).
Fields of papers citing papers by Ignacio Melero
This network shows the impact of papers produced by Ignacio Melero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ignacio Melero. The network helps show where Ignacio Melero may publish in the future.
Co-authors
The 25 scholars most cited alongside Ignacio Melero, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 467 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Hit paper breakdown → | 2017 | 3584 |
| 2 | Dendritic cells in cancer immunology and immunotherapy Hit paper breakdown → | 2019 | 2086 |
| 3 | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Hit paper breakdown → | 2020 | 1068 |
| 4 | Advances in immunotherapy for hepatocellular carcinoma Hit paper breakdown → | 2021 | 1008 |
| 5 | Cytokines in clinical cancer immunotherapy Hit paper breakdown → | 2018 | 979 |
| 6 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial Hit paper breakdown → | 2021 | 890 |
| 7 | A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C Hit paper breakdown → | 2013 | 841 |
| 8 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial Hit paper breakdown → | 2022 | 821 |
| 9 | Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors Hit paper breakdown → | 1997 | 797 |
| 10 | Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3 Hit paper breakdown → | 2018 | 730 |
| 11 | Therapeutic vaccines for cancer: an overview of clinical trials Hit paper breakdown → | 2014 | 668 |
| 12 | Cancer vaccines: the next immunotherapy frontier Hit paper breakdown → | 2022 | 657 |
| 13 | CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity Hit paper breakdown → | 2020 | 648 |
| 14 | Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer Hit paper breakdown → | 2017 | 625 |
| 15 | Evolving synergistic combinations of targeted immunotherapies to combat cancer Hit paper breakdown → | 2015 | 564 |
| 16 | Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma Hit paper breakdown → | 2019 | 540 |
| 17 | 2007 | 532 | |
| 18 | Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes Hit paper breakdown → | 2019 | 522 |
| 19 | Immunological landscape and immunotherapy of hepatocellular carcinoma Hit paper breakdown → | 2015 | 500 |
| 20 | Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors Hit paper breakdown → | 2020 | 434 |
About Ignacio Melero
Ignacio Melero is a scholar working on Oncology, Immunology, Hepatology, Radiology, Nuclear Medicine and Imaging and Genetics, having authored 467 papers that have together received 43.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (217 papers), Immunotherapy and Immune Responses (154 papers), Immune Cell Function and Interaction (29 papers), T-cell and B-cell Immunology (28 papers), Hepatocellular Carcinoma Treatment and Prognosis (28 papers), Monoclonal and Polyclonal Antibodies Research (28 papers), Virus-based gene therapy research (28 papers) and Immune cells in cancer (12 papers). The work is most often cited by research in Oncology (18.4k citations), Hepatology (7k citations), Immunology (13k citations), Cancer Research (1.5k citations) and Genetics (876 citations). Ignacio Melero has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Jose Luis Perez-Gracia, Miguel F. Sanmamed, Maria Esperanza Rodriguez-Ruiz, Bruno Sangro, Sandra Hervás‐Stubbs, Jesús Prìeto, David Sancho, Lieping Chen, Pedro Berraondo and Francisco J. Cueto. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, OncoImmunology and Cancer Discovery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.